Results 31 to 40 of about 2,806 (137)

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib [PDF]

, 2016
Activating mutations in MYD88 are present in approximately 95% of patients with Waldenstrom Macroglobulinemia (WM), as well as other B-cell malignancies including ABC DLBCL. In WM, mutated MYD88 triggers activation of BTK. Ibrutinib, a pleiotropic kinase
Advani, Bohers, Cao, Cao, Cheng, Chng, Christopher J. Patterson, Evans, Farré, Gay, Guang Yang, Gutiérrez, Hallek, Hanke, Hong, Honigberg, Janz, Jennifer R. Brown, Jiaji G. Chen, Jie Chen, Jorge J. Castillo, Jourdan, Juilland, Lam, Leleu, Li Tan, Lian Xu, Messeguer, Musumeci, Nathanael Gray, Ngo, Nicholas Tsakmaklis, O’Boyle, Patricelli, Pecquet, Pene-Dumitrescu, Philip Cohen, Poh, Sahota, Saito, Sanner, Sara J. Buhrlage, Schaeffer, Shuai Liu, Steven P. Treon, Suh, Taguchi, Treon, Treon, Treon, Trott, Varettoni, Wei Zhang, Wilson, Woyach, Xia Liu, Xiaofeng Zhang, Xu, Yang, Yang, Zachary R. Hunter   +60 more
core   +2 more sources

Current approach to Waldenström Macroglobulinemia

Cancer Treatment and Research Communications, 2022
Waldenström Macroglobulinemia (WM) is a unique, low grade, IgM lymphoplasmacytic lymphoma with a heterogeneous clinical course. A paucity of high-grade evidence from large phase 3 trials remains a major issue in the field despite a rapidly expanding ...
Gayathri Ravi, Prashant Kapoor
doaj   +1 more source

Primary central nervous system diffuse large B‐cell lymphoma masqueraded as Bing‐Neel syndrome: Steps in management and review of future directions

Clinical Case Reports, 2021
Bing‐Neel syndrome (BNS) remains a rare complication of Waldenstrom Macroglobulinemia. Given the paucity of this disease, treatment guidelines are based on small clinical trials with limited participants.
Lukas Delasos, Deep Phachu, Nishka Shetty, Melissa Sepulveda‐Ramos, James Vredenburgh   +4 more
doaj   +1 more source

Overexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma [PDF]

, 2017
published_or_final_versio
Guan, X, Huang, PZ, Li, MQ, Zhang, BZ, Zhu, YH   +4 more
core   +1 more source

WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

Mediterranean Journal of Hematology and Infectious Diseases, 2018
Waldenstrom Macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features. Diagnostic and prognostic charactrization in WM significantly changed with the discovery of two molecular markers: MYD88 and CXCR4. Mutational status
Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi   +4 more
doaj   +1 more source

Lymphoplasmacytic lymphoma relapse presenting as isolated multifocal subcutaneous adipose tissue infiltrates on 18F-FDG PET/CT

Acta Radiologica Open, 2023
Lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM) is an uncommon mature B cell lymphoma usually involving the bone marrow and, less commonly, the spleen and/or lymph nodes.
Saša Anžej Doma, Andrej Doma
doaj   +1 more source

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, EarlyView.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature

Clinical Case Reports, 2021
Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL, and management is poorly understood.
Mizba Baksh, Liuyan Jiang, Unnati Bhatia, Victoria Alegria, Taimur Sher, Vivek Roy, Asher Chanan‐Khan, Sikander Ailawadhi, Ricardo D. Parrondo   +8 more
doaj   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, Volume 117, Issue 1, Page 144-153, July 2026.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Regulation of class IIa HDAC activities: It is not only matter of subcellular localization [PDF]

, 2016
In response to environmental cues, enzymes that influence the functions of proteins, through reversible post-translational modifications supervise the coordination of cell behavior like orchestral conductors. Class IIa histone deacetylases (HDACs) belong
Brancolini, Claudio, DI GIORGIO, Eros
core   +1 more source